Recombinant human IFN-gamma (Cat.NO. HZ-1301) inhibits HT-29 cell line (human colorectal adenocarcinoma cell line) proliferation in the prescence of 0.5 ng/mL TNF alpha in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IFN-gamma (2ng/mL HZ-1301 axis) is neutralized by mouse anti-human IFN-gamma monoclonal antibody 69007-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 100-500 ng/mL. This data was developed using the same antibody clone with 69007-1-PBS in a different storage buffer formulation.

Recombinant human IFN-gamma (Cat.NO. HZ-1301) inhibits HT-29 cell line (human colorectal adenocarcinoma cell line) proliferation in the prescence of 0.5 ng/mL TNF alpha in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IFN-gamma (5 ng/mL HZ-1301 axis) is neutralized by mouse anti-human IFN-gamma monoclonal antibody 69007-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 100-500 ng/mL. The NeutraControl mouse anti-human IFN-gamma monoclonal antibody 69507-1-Ig could recognize human IFN-gamma but could not neutralize human IFN-gamma in the range of 0.00244-40 μg/mL (green curve, refer to top X-right Y axis). This data was developed using the same antibody clone with 69007-1-PBS in a different storage buffer formulation.

Indirect ELISA was carried out by coating recombinant Human IFN gamma (Cat.NO. HZ-1301) at 70 ng/well followed by blocking and adding serial diluted IFN gamma antibody 69007-1-Ig and 69507-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm. This data was developed using the same antibody clone with 69007-1-PBS in a different storage buffer formulation.